Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  HIV Infection

  Free Subscription


19.05.2025

3 AIDS
1 AIDS Res Hum Retroviruses
6 Clin Infect Dis
1 Drugs
1 HIV Med
5 J Acquir Immune Defic Syndr
2 J Infect Dis
2 J Virol
1 JAMA
2 N Engl J Med
10 PLoS One
1 PLoS Pathog
2 Science
1 Vaccine


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AIDS

  1. NICASTRO TM, Mocello AR, Weke E, Bukusi EA, et al
    Effect of a climate-smart intervention on agriculture and nutrition of people with HIV: a cluster-randomized trial.
    AIDS. 2025 May 15. doi: 10.1097/QAD.0000000000004234.
    PubMed         Abstract available

  2. HAMILTON DT, Hoover KW, Delaney KP
    Reducing HIV incidence in the southern US through routine opt-out HIV screening.
    AIDS. 2025 May 15. doi: 10.1097/QAD.0000000000004237.
    PubMed         Abstract available

  3. APPLETON AA, Lee S, Kuniholm MH, Vasquez E, et al
    Adverse childhood experiences, sexual orientation-related victimization, and cardiovascular disease risk among men living with and without HIV.
    AIDS. 2025 May 15. doi: 10.1097/QAD.0000000000004235.
    PubMed         Abstract available


    AIDS Res Hum Retroviruses

  4. LI H, Guo Q, Feng Y, Liao L, et al
    Identification of Two Novel HIV-1 Unique Recombinant Forms Among Men Who Have Sex with Men in Northern China.
    AIDS Res Hum Retroviruses. 2025 May 15. doi: 10.1089/aid.2024.0131.
    PubMed         Abstract available


    Clin Infect Dis

  5. STURNY-LECLERE A, Francoise U, Badje AD, Garcia-Hermoso D, et al
    Histoplasma antigenuria prevalence in patients with advanced HIV disease in Cote d'Ivoire: a prospective trial ancillary study.
    Clin Infect Dis. 2025 May 16:ciaf237. doi: 10.1093.
    PubMed         Abstract available

  6. HAN WM, Ryom L, Sabin CA, Greenberg L, et al
    Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort.
    Clin Infect Dis. 2025 May 15:ciaf248. doi: 10.1093.
    PubMed         Abstract available

  7. SCHWARTZ IS, Pasqualotto AC
    Histoplasma antigen screening in advanced HIV disease.
    Clin Infect Dis. 2025 May 13:ciaf238. doi: 10.1093.
    PubMed        

  8. KONOPNICKI D, Gilles C, Manigart Y, Barlow P, et al
    Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial.
    Clin Infect Dis. 2025 May 13:ciaf241. doi: 10.1093.
    PubMed         Abstract available

  9. HAWKINS KL, Dandachi D, Verzani Z, Brannock MD, et al
    HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record Based Cohort Study.
    Clin Infect Dis. 2025 May 12:ciaf242. doi: 10.1093.
    PubMed         Abstract available

  10. STADLER JAM, Kuhlin JJ, Molloy SF, Mtwa NN, et al
    Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.
    Clin Infect Dis. 2025 May 9:ciaf112. doi: 10.1093.
    PubMed         Abstract available


    Drugs

  11. GARLAND JM, Mayan H, Kantor R
    Treatment of Advanced HIV in the Modern Era.
    Drugs. 2025 May 12. doi: 10.1007/s40265-025-02181.
    PubMed         Abstract available


    HIV Med

  12. VAN BECKHOVEN D, Serrien B, Demeester R, Van Praet J, et al
    Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022.
    HIV Med. 2025 May 12. doi: 10.1111/hiv.70027.
    PubMed         Abstract available


    J Acquir Immune Defic Syndr

  13. ONWUBIKO UN, Benkeser D, Holland DP, Baral SD, et al
    Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.
    J Acquir Immune Defic Syndr. 2025 May 15. doi: 10.1097/QAI.0000000000003698.
    PubMed         Abstract available

  14. HUANG YA, Patel RR, Mann LM, Zhu W, et al
    Out-of-pocket costs for PrEP ancillary services among U.S. commercially insured persons, 2017-2022.
    J Acquir Immune Defic Syndr. 2025 May 14. doi: 10.1097/QAI.0000000000003695.
    PubMed         Abstract available

  15. PATTEN G, Haas AD, Davies MA, Maartens G, et al
    Association between changes in script renewal periods and HIV viral non-suppression: a cohort study of a South African private-sector HIV program.
    J Acquir Immune Defic Syndr. 2025 May 14. doi: 10.1097/QAI.0000000000003697.
    PubMed         Abstract available

  16. SUDDERUDDIN H, Dang Z, Watson B, Atkinson K, et al
    Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples.
    J Acquir Immune Defic Syndr. 2025 May 13. doi: 10.1097/QAI.0000000000003694.
    PubMed         Abstract available

  17. CRESSEY TR, Salvadori N, Rabie H, du Toit S, et al
    Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study.
    J Acquir Immune Defic Syndr. 2025;99:195-201.
    PubMed         Abstract available


    J Infect Dis

  18. YU F, Ma P, Duan J
    Reevaluating the clinical relevance of bacterial vaginosis-associated immune responses in HIV infection.
    J Infect Dis. 2025 May 14:jiaf227. doi: 10.1093.
    PubMed        

  19. ROBINSON-PAPP J, Mehta M, Mueller BR, Neupane N, et al
    Gastrointestinal Dysmotility, Autonomic Function and Small Intestinal Bacterial Overgrowth among People with Well-Controlled HIV.
    J Infect Dis. 2025 May 13:jiaf238. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  20. GREBER UF
    Clicking viruses-with chemistry toward mechanisms in infection.
    J Virol. 2025 May 14:e0047125. doi: 10.1128/jvi.00471.
    PubMed         Abstract available

  21. SUTAR J, Jayal P, Mullick R, Chaudhary S, et al
    Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies.
    J Virol. 2025 May 16:e0000825. doi: 10.1128/jvi.00008.
    PubMed         Abstract available


    JAMA

  22. ANDERER S
    One Million New Pediatric HIV Cases Predicted If PEPFAR Funding Is Cut.
    JAMA. 2025 May 9. doi: 10.1001/jama.2025.6155.
    PubMed        


    N Engl J Med

  23. MUSIIME V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, et al
    Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
    N Engl J Med. 2025;392:1917-1932.
    PubMed         Abstract available

  24. ROBERTS ET, Phelan J, Schwartz AL, Meara E, et al
    Loss of Subsidized Drug Coverage and Mortality among Medicare Beneficiaries.
    N Engl J Med. 2025 May 14. doi: 10.1056/NEJMsa2414435.
    PubMed         Abstract available


    PLoS One


  25. Editorial Note: Metabarcoding analysis of eukaryotic microbiota in the gut of HIV-infected patients.
    PLoS One. 2025;20:e0324348.
    PubMed        

  26. PLATT L, Wut Yee Kyaw K, Rathod SD, Yu Naing A, et al
    The effect of location in mining or borderland areas on HIV incidence among people who use drugs attending a harm reduction programme in Myanmar, 2014-2021: A retrospective cohort study.
    PLoS One. 2025;20:e0295727.
    PubMed         Abstract available

  27. ARNOLD EA, Fuller S, Agins BD, Fidelak L, et al
    Sheltering from the storm: The role of a quality improvement collaborative focused on improving HIV care retention in New Orleans during and following Hurricane Ida.
    PLoS One. 2025;20:e0323026.
    PubMed         Abstract available

  28. NTSHIQA T, Velen K, Ginindza S, Nhlangulela L, et al
    Resistance to tuberculin skin test/interferon-gamma release assay conversion among highly TB exposed, HIV infected goldminers in South Africa.
    PLoS One. 2025;20:e0318819.
    PubMed         Abstract available

  29. CHAVEZ JV, Davis Ewart L, Ilyas O, Ghanooni D, et al
    'I was like, this is gonna hurt': Implementing self-sampling of dried blood spots to measure HIV viral load.
    PLoS One. 2025;20:e0322740.
    PubMed         Abstract available

  30. NWANJA E, Akpan U, Toyo O, Onwah O, et al
    Treatment outcomes among young persons living with HIV who transitioned to adult care in southern Nigeria: A retrospective cohort study.
    PLoS One. 2025;20:e0321962.
    PubMed         Abstract available

  31. SIAME L, Mutalange M, Chanda C, Sakala M, et al
    The effect of the universal test and treat strategy on the kidney function in adults living with HIV in Zambia: A six-month multicenter cohort study.
    PLoS One. 2025;20:e0323618.
    PubMed         Abstract available

  32. KIMMEL AD, Pan Z, Brazier E, Murenzi G, et al
    Development and calibration of a mathematical model of HIV outcomes among Rwandan adults: Informing achievement of global targets across sub-populations in Rwanda.
    PLoS One. 2025;20:e0310662.
    PubMed         Abstract available

  33. SALIHU A, Jahun I, Olusegun Oyedeji D, Fajemisin W, et al
    Ensuring equitable access to quality HIV care for affected populations in complex sociocultural settings: Lessons from Nigeria.
    PLoS One. 2025;20:e0319807.
    PubMed         Abstract available

  34. TUMUHAIRWE F, Izudi J, Munina A, Bashaija A, et al
    Quality of life and retention in care among people living with HIV initiated on ART in the era of "Universal Test and Treat" policy at a large HIV Clinic in South Western Uganda.
    PLoS One. 2025;20:e0324024.
    PubMed         Abstract available


    PLoS Pathog

  35. DZHIVHUHO GA, Jackson PEH, Honeycutt ES, Mesquita FDS, et al
    Rev-RRE activity modulates HIV-1 replication and latency reactivation: Implications for viral persistence and cure strategies.
    PLoS Pathog. 2025;21:e1012885.
    PubMed         Abstract available


    Science

  36. WILLIS JR, Prabhakaran M, Muthui M, Naidoo A, et al
    Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
    Science. 2025 May 15:eadr8382. doi: 10.1126/science.adr8382.
    PubMed         Abstract available

  37. CANIELS TG, Prabhakaran M, Ozorowski G, MacPhee KJ, et al
    Precise targeting of HIV broadly neutralizing antibody precursors in humans.
    Science. 2025 May 15:eadv5572. doi: 10.1126/science.adv5572.
    PubMed         Abstract available


    Vaccine

  38. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.